Britain and America have established a major bilateral deal that will maintain zero import taxes on British drug products being sold in the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has pledged to increase funding on medicines through the National Health Service (NHS). This commitment secures that duties on these vital products will be held at zero for a duration of the next three years.
This agreement comes after earlier statements to hike duties on patented pharmaceutical products, with increases floated up to 100%.
"This arrangement with the UK strengthens the global environment for cutting-edge drugs and brings much-needed fairness to transatlantic medicine commerce," a release declared.
Commercial Impact
Pharmaceuticals constitute one of the Britain's biggest goods shipped to the United States, which is by far the primary market for large companies like GSK and AstraZeneca.
Trade data show that in the one-year period to the end of last September, the UK exported drugs valued at £11.1bn to the US. This value accounted for nearly one-fifth of total UK exports in that timeframe.
"This agreement protects work, increases capital expenditure and facilitates the UK to establish itself as a international leader for biotech and pharma," a minister stated.
Key UK Commitments
The deal includes several notable changes from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it judges new treatments to be too expensive by a quarter.
- Higher Drug Budget: There is a aim to double total public funding on medicines from 0.3 percent of the national economy to 0.6% over the next decade.
- Rebate Cap: The sum manufacturers must pay back to the NHS to prevent overspending will be restricted at 15%. Last year, refunds topped twenty percent.
Industry Background
The deal comes amid a ongoing dispute between the drug companies and the UK government over drug pricing and regulatory access.
The disagreement were intensified by assertions that US customers were paying significantly more for the same drugs than consumers in the UK and Europe.
In recent months, several large drug company projects in the UK have been halted or abandoned, while multi-billion-dollar investments have been announced toward projects in the United States.
A senior figure stated that the NHS needed to spend more on treatments, noting that its budget allocation on drugs had shrunk as a share of its resources over the last ten years.
